Shares of Marksans Pharma Ltd surged around 8% on May 26 after the company reported a strong set of Q4FY26 earnings, driven by healthy revenue growth and sharp margin expansion.
The stock was trading at ₹235.71, up 7.01% at around 1:01 PM, after touching an intraday high of ₹238.90 on the NSE. Trading volumes also remained strong following the earnings announcement.
For the quarter ended March 2026, the company reported consolidated revenue from operations of ₹856.11 crore, compared with ₹708.46 crore in the corresponding quarter last year.
Based on the reported financials, EBITDA for Q4FY26 stood at ₹195.42 crore against ₹126.94 crore in Q4FY25. EBITDA margin expanded significantly to 22.8% from 17.9% a year ago.
Profit after tax for the quarter rose sharply to ₹149.03 crore from ₹90.73 crore reported in the corresponding period last year.
Total income during the quarter increased to ₹891.29 crore from ₹723.80 crore in Q4FY25, while profit before tax climbed to ₹200 crore from ₹116.09 crore a year earlier.
Sequentially too, the company reported improvement in performance. Revenue from operations rose from ₹754.43 crore in Q3FY26 to ₹856.11 crore in Q4FY26, while PAT increased from ₹113.69 crore to ₹149.03 crore.
The company also reported total comprehensive income of ₹202.97 crore during the quarter compared with ₹117.21 crore in the year-ago period, aided by foreign currency translation gains.
Market participants appeared to react positively to the strong profitability growth and margin expansion, helping the stock outperform broader market moves during the session.
At the current market price, the stock remains below its 52-week high of ₹270.70, while comfortably above its 52-week low of ₹155.
Disclaimer: This article is based on company filings and market data. Investors are advised to consult certified financial advisors before making investment decisions.